Shanghai MicroPort MedBot Group (2252) H2 2024 earnings summary

Executive summary

• Achieved record revenue of RMB 257.2 million, up 146% year-over-year, driven by strong domestic and overseas sales growth.

• Adjusted net loss narrowed by 45% year-over-year to RMB 482.6 million, reflecting improved operational efficiency and cost optimization.

• Net loss narrowed by 36.8% to RMB 647.1 million, reflecting higher gross profit, reduced R&D and administrative expenses, partially offset by an impairment loss on an overseas investment.

• Major products, Toumai and SkyWalker, achieved significant commercialisation milestones, with global orders and installations rising sharply.

• Maintained leadership in clinical operations and remote surgery technology, setting multiple world records and expanding the global remote surgery network.

Financial highlights

• Revenue reached RMB 257.2 million, a 146% increase compared to the previous year.

• Gross profit increased to RMB 86.2 million, up 487% year-over-year, with gross profit margin rising to 34% from 14%.

• Total net loss decreased to RMB 647.1 million from RMB 1,023.5 million in 2023; adjusted net loss was RMB 482.6 million, narrowing by 45% year-over-year.

• Free cash outflow reduced to RMB 388.3 million, a 42% improvement year-over-year.

• R&D expenses declined 46% year-over-year to RMB 308.7 million; selling and marketing expenses decreased 13% to RMB 207.9 million; administrative expenses dropped 56% to RMB 55.3 million.

Outlook and guidance

• Positioned for continued financial improvement based on cost reduction and efficiency initiatives.

• Anticipates further global market penetration and product commercialization, with plans to strengthen product portfolio and expand global presence.

• Focus on building a multi-specialty surgical platform and increasing market penetration in lower-tier markets.